… The results of this clinical trial may be of particular interest to physicians treating older …
together with potentially longer duration of diabetes, older patients are likely to be at increased risk …

… medical therapy, enrolling patients from May 2013 to June 2015. Eligible patients with
established ASCVD had to be 40 years of age or older … older and women 60 years of age or older …

… The last study visit followed this period. … Similarly, in the present study, a small initial
decrease in eGFR with dapagliflozin was observed for all treatment groups and this did not appear …

… ) 60–89 mL/min per 1.73 m 2 , 61%; moderate eGFR 30–59 mL/min per 1.73 m 2 , 15%) was
observed at baseline in the present study than in previous placebo-controlled dapagliflozin …

… Randomized controlled trials (RCTs), with treatment interventions that lasted at least 12 weeks,
were collected. Non-human studies, letters… The last observations carried out were used to …

… a difference between the dapagliflozin and placebo group of … With last patient last visit for
the study planned for September … trial with last randomized patient at March 2019 and a study …

… This study investigated the effect of dapagliflozin on EAT volume and P-wave indices. …
present study were 48 ms and 15 ms in the dapagliflozin group and 44 ms and 14 ms in the control …

… indicate that dapagliflozin treatment reduced cardiac preload and are in line with recent
findings of … Björkgren, Uppsala Clinical Research Center, for valuable support with editing and …

… The treatment groups were generally balanced with respect to demographics … dapagliflozin
treatment arm (Table 1). Most patients were white, had a mean age of 61 years, had a prior …

… In this ‘proof of concept’ randomized controlled trial, we hypothesized that dapagliflozin
would … Participants had to have an HbA1c measurement within the last 6 months at screening …